Skip to main content

MODULACION DEL ENVEJECIMIENTO Y LA NEURODEGENERACION POR MOLECULAS PEQUEÑAS INHIBIDORAS DE PROTEINA QUINASAS

PID2019-105600RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 34
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration?

  • Brackhan, Mirjam
  • Arribas Blázquez, Marina
  • Lastres-Becker, Isabel
Although the trigger for the neurodegenerative disease process is unknown, the relevance of aging stands out as a major risk for the development of neurodegeneration. In this review, we highlighted the relationship between the different cellular mechanisms that occur as a consequence of aging and transcription factor nuclear factor erythroid-2-related factor 2 (NRF2) and the connection with the TAU protein. We focused on the relevance of NRF2 in the main processes involved in neurodegeneration and associated with aging, such as genomic instability, protein degradation systems (proteasomes/autophagy), cellular senescence, and stem cell exhaustion, as well as inflammation. We also analyzed the effect of aging on TAU protein levels and its aggregation and spread process. Finally, we investigated the interconnection between NRF2 and TAU and the relevance of alterations in the NRF2 signaling pathway in both primary and secondary tauopathies. All these points highlight NRF2 as a possible therapeutic target for tauopathies.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis

  • Rojas-Prats, Elisa
  • Martínez-González, Loreto
  • Gonzalo-Consuegra, Claudia
  • Liachko, Nicole F.
  • Pérez, Concepción
  • Ramírez, David
  • Kraemer, Brian C.
  • Martín-Requero, Ángeles
  • Pérez, Daniel I.
  • Gil, Carmen
  • De Lago, E.
  • Martínez Gil, Ana
58 p.-11 fig.-2 tab., Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no known cure. Aggregates of the nuclear protein TDP-43 have been recognized as a hallmark of proteinopathy in both familial and sporadic cases of ALS. Post-translational modifications of this protein, include hyperphosphorylation, cause disruption of TDP-43 homeostasis and as a consequence, promotion of its neurotoxicity. Among the kinases involved in these changes, cell division cycle kinase 7 (CDC7) plays an important role by directly phosphorylating TDP-43. In the present manuscript the discovery, synthesis, and optimization of a new family of selective and ATP-competitive CDC7 inhibitors based on 6-mercaptopurine scaffold are described. Moreover, we demonstrate the ability of these inhibitors to reduce TDP-43 phosphorylation in both cell cultures and transgenic animal models such as C. elegans and Prp-hTDP43 (A315T) mice. Altogether, the compounds described here may be useful as versatile tools to explore the role of CDC7 in TDP-43 phosphorylation and also as new drug candidates for the future development of ALS therapies., This work was supported by Comunidad de Madrid (grant B2017/BMD-3813), MINECO (grant SAF2016-76693-R and PID2019-105600RB-I00 to A.M., RTI2018-0988885-B-I00 to E.dL. and CTQ2015-66313-R to A.M.R.), ISCii CIBERNED (CB18/05/00040 to A.M., C.G. and A.M.R, and CB06/05/0089 to E.dL.), MECD (FPU14-00204. to E.R.), the National Institutes of Health (R01NS064131 to B.C.K.) and the Department of Veterans Affairs (Merit Review Grants I01BX003755 to B.C.K. and I01BX004044 to N.F.L.), CONICYT-PCI (grant REDES190074 to D.R. and A.M.) and FONDECYT (grant no. 11180604 to D.R.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Kinase inhibitors as underexplored antiviral agents

  • Garcia-Carceles, Javier
  • Caballero, Elena
  • Gil, Carmen
  • Martínez Gil, Ana
73 p.-12 fig.-1 tab.-1 graph. abst., Viral infections are a major health problem; therefore, there is an urgent need for novel therapeutic strategies.Antivirals used to target proteins encoded by the viral genome usually enhance drug resistance generated by the virus. A potentialsolution may be drugs acting at host-based targets since viruses are dependent on numerous cellular proteins and phosphorylationevents that are crucial during their life cycle. Repurposing existing kinase inhibitors as antiviral agents would help in the cost andeffectiveness of the process, but this strategy usually does not provide much improvement, and specific medicinal chemistryprograms are needed in thefield. Anyway, extensive use of FDA-approved kinase inhibitors has been quite useful in deciphering therole of host kinases in viral infection. The present perspective aims to review the state of the art of kinase inhibitors that target viralinfections in different development stages., Funding from“la Caixa”Banking Foundation (LCF/PR/HR19/52160012), CSIC (202020E103 and 202080E293),and AEI (Grant PID2019-105600RB-I00) is acknowledged.E.C. holds a JAE Intro fellowship (JAEINT_20_01339) from CSIC., Peer reviewed, postprint
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

From kinase inhibitors to multitarget ligands as powerful drug leads for Alzheimer’s disease using protein-templated synthesis

  • Martínez Gil, Ana
  • Nozal, Vanesa
  • García-Rubia, Alfonso
  • Cuevas, Eva P.
  • Pérez, Concepción
  • Palomo, Valle
  • Tosat-Bitrian, Carlota
  • Bartolomé Robledo, Fernando
  • Carro, Eva
  • Ramírez, David
12 p.-12 fig.-3 tab.-5 schem., Multitarget directed ligands (MTDLs) are arising as promising tools to tackle complex diseases. The main goal of this work is to create powerful modulating agents for neurodegenerative disorders. To achieve this aim, we have combined fragments that inhibit key protein kinases involved in the main pathomolecular pathways of Alzheimer’s disease (AD) such as tau aggregation, neuroinflammation and decreased neurogenesis, whilst looking for a third action in beta-secretase (BACE1), responsible of β-amyloid production. We obtained well-balanced MTDLs with in vitro activity in three different relevant targets and efficacy in two cellular models of AD. Furthermore, computational studies confirmed how these compounds accommodate adequately into the long and rather narrow BACE1 catalytic site. Finally, we employed in situ click chemistry using BACE1 as protein template as a versatile synthetic tool that allowed us to obtain further MTDLs., This work was supported by MINECO (grant SAF2016-76693-R and PID2019-105600RB-I00 to A.M.), ISCiii_CIBERNED (CB18/05/00040 to A.M and A.G.-R., and CB07/502 to E.C. and F.B.), ISCiii_FIS (grant PI18/00118 to E.C.), MECD (FPU16- 04466 to V.N., and FPU18-06310 to C.T.B.), CONICYT-PCI (grant REDES190074 to D.R. and A.M.) and FONDECYT (grant no. 11180604 to D.R.). V.P. has received financial support through the Postdoctoral Junior Leader Fellowship Program (LCF/BQ/PR18/11640007) from “la Caixa” Banking Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Small molecule inhibitors of mammalian GSK-3β promote in vitro plant cell reprogramming and somatic embryogenesis in crop and forest species

  • Berenguer, Eduardo
  • Carneros, Elena
  • Pérez-Pérez, Yolanda
  • Gil, Carmen
  • Martínez Gil, Ana
  • Testillano, Pilar S.
18 p.-10 fig., Plant in vitro regeneration systems, like somatic embryogenesis, are essential in breeding; they permit to propagate elite genotypes, to produce doubled-haploids, and to convert gene editing or transformation events into plants. However, in many crop and forest species somatic embryogenesis is highly inefficient. We report a new strategy to improve in vitro embryogenesis using synthetic small molecule inhibitors of mammalian glycogen synthase kinase 3β (GSK-3β), never used in plants. These inhibitors increased in vitro embryo production in three different systems and species, microspore embryogenesis of Brassica napus and Hordeum vulgare, and somatic embryogenesis of Quercus suber. TDZD-8, representative compound of the molecules tested, inhibited GSK-3 activity in microspore cultures, and increased expression of embryogenesis- genes FUS3, LEC2 and AGL15. Plant GSK-3 kinase BIN2 is master regulator of brassinosteroid (BR) signalling. During microspore embryogenesis, BR biosynthesis and signalling genes CPD, GSK-3-BIN2, BES1 and BZR1 were upregulated and BAS1 catabolic gene was repressed, indicating activation of BR pathway. TDZD-8 increased expression of BR signalling elements, mimicking BR effects. The findings support that the small molecule inhibitors promoted somatic embryogenesis by activating the BR pathway, opening the way for new strategies using GSK-3β inhibitors that could be extended to other species., Work supported by the Spanish National Agency of Research (Agencia Estatal de Investigación, AEI) and European Regional Development Fund (ERDF/FEDER) [grants AGL2017-82447-R and PID2020-113018RB-I00 to PST; and SAF2016-76693-R and PID2019-105600RB-I00 to AM], Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Phenotypic assay leads to discovery of mitophagy inducers with therapeutic potential for Parkinson’s disease

  • Maestro, Inés
  • De la Ballina, Laura R.
  • Simonsen, Anne
  • Boya, Patricia
  • Martínez Gil, Ana
12 p.-9 fig.-2 tab.-1 graph. abst., Mitophagy, the selective degradation of mitochondria by autophagy, involved in important physiological processes and defects in pathways has been reported in pathological conditions, such as neurodegeneration. Thus, mitophagy is an interesting target for drug discovery programs. In this investigation, we used robust phenotypic assay to screen a set of 50 small heterocyclic compounds to identify inducers of mitophagy. We identified two compounds, VP07 and JAR1.39, that induce Parkin-dependent mitophagy. Based on structure–activity relationship studies, we proposed the ability of the compounds to act as light chain 3 (LC3) interactors, similar to cardiolipin or ceramide, triggering mitophagy via Pink1/Parkin. Finally, we show promising therapeutic applicability in a cellular model of Parkinson’s disease., This research was supported by the H2020-MSCA-ITN-2017(grant no. 765912) DRIVE project, Spain’s Ministerio de Ciencia e Innovación (grant nos. PGC2018-098557-B-I00 to P.B. and PID2019-105600RB-I00 to A.M.), FRIPRO (project no. 221831 to A.S.), and the Research Council of Norway through its Centres of Excellence funding scheme (project no.262652)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Increasing brain permeability of PHA-767491, a cell division cycle 7 kinase inhibitor, with biodegradable polymeric nanoparticles

  • Rojas-Prats, Elisa
  • Tosat-Bitrian, Carlota
  • Martínez-González, Loreto
  • Nozal, Vanesa
  • Pérez, Daniel I.
  • Martínez Gil, Ana
15 p.-8 fig.-2 tab., A potent cell division cycle 7 (CDC7) kinase inhibitor, known as PHA-767491, has been described to reduce the transactive response DNA binding protein of 43 KDa (TDP-43) phosphorylation in vitro and in vivo, which is one of the main proteins found to aggregate and accumulate in the cytoplasm of motoneurons in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients. However, the main drawback of this compound is its low permeability to the central nervous system (CNS), limiting its use for the treatment of neurological conditions. In this context, the use of drug delivery systems like nanocarriers has become an interesting approach to improve drug release to the CNS. In this study, we prepared and characterized biodegradable nanoparticles in order to encapsulate PHA-767491 and improve its permeability to the CNS. Our results demonstrate that poly (lactic-co-glycolic acid) (PLGA) nanoparticles with an average radius between 145 and 155 nm could be used to entrap PHA-767491 and enhance the permeability of this compound through the blood–brain barrier (BBB), becoming a promising candidate for the treatment of TDP-43 proteinopathies such as ALS., This research was funded by Comunidad de Madrid (grant B2017/BMD-3813), ISCiii CIBERNED (CB18/05/00040), MINECO (grant SAF2016-76693-R and PID2019-105600RB-I00), and MECD (FPU14-00204 to E.R.P., FPU16-04466 to V.N., and FPU18-06310 to C.T.B.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Molecular alterations in sporadic and SOD1-ALS immortalized lymphocytes: towards a personalized therapy

  • Lastres-Becker, Isabel
  • Porras, Gracia
  • Arribas-Blázquez, Marina
  • Maestro, Inés
  • Borrego-Hernández, Daniel
  • Boya, Patricia
  • Cerdán, Sebastián
  • García-Redondo, Alberto
  • Martínez Gil, Ana
  • Martín-Requero, Ángeles
17 p.-6 fig.-1 tab., Amyotrophic lateral sclerosis (ALS) is a fatal neurological condition where motor neurons (MNs) degenerate. Most of the ALS cases are sporadic (sALS), whereas 10% are hereditarily transmitted (fALS), among which mutations are found in the gene that codes for the enzyme superoxide dismutase 1 (SOD1). A central question in ALS field is whether causative mutations display selective alterations not found in sALS patients, or they converge on shared molecular pathways. To identify specific and common mechanisms for designing appropriate therapeutic interventions, we focused on the SOD1-mutated (SOD1-ALS) versus sALS patients. Since ALS pathology involves different cell types other than MNs, we generated lymphoblastoid cell lines (LCLs) from sALS and SOD1-ALS patients and healthy donors and investigated whether they show changes in oxidative stress, mitochondrial dysfunction, metabolic disturbances, the antioxidant NRF2 pathway, inflammatory profile, and autophagic flux. Both oxidative phosphorylation and glycolysis appear to be upregulated in lymphoblasts from sALS and SOD1-ALS. Our results indicate significant differences in NRF2/ARE pathway between sALS and SOD1-ALS lymphoblasts. Furthermore, levels of inflammatory cytokines and autophagic flux discriminate between sALS and SOD1-ALS lymphoblasts. Overall, different molecular mechanisms are involved in sALS and SOD1-ALS patients and thus, personalized medicine should be developed for each case., This research was funded by Comunidad de Madrid (grant ELA_Madrid B2017/BMD-3813 and S2017/BMD-3688), European Commission MSCA-ITN-ETN (grant DRIVE GA: 765912), ISCiii (CIBERNED CB18/05/000 and CB06/05/0089), Fundela (2019/00325/001) for I.L.-B. and AEI (grant PID2019-105600RB-I00) for, A.M. and I.L.-B., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Tideglusib, a non-ATP competitive inhibitor of GSK-3β as a drug candidate for the treatment of amyotrophic lateral sclerosis

  • Martínez-González, Loreto
  • Gonzalo-Consuegra, Claudia
  • Gómez-Almería, Marta
  • Porras, Gracia
  • De Lago, E.
  • Martín-Requero, Ángeles
  • Martínez Gil, Ana
14 p.-6 fig.-2 tab., Amyotrophic Lateral Sclerosis (ALS) is the most common degenerative motor neuron disease in adults. About 97% of ALS patients present TDP-43 aggregates with post-translational modifications, such as hyperphosphorylation, in the cytoplasm of affected cells. GSK-3β is one of the protein kinases involved in TDP-43 phosphorylation. Up-regulation of its expression and activity is reported on spinal cord and cortex tissues of ALS patients. Here, we propose the repurposing of Tideglusib, an in-house non-ATP competitive GSK-3β inhibitor that is currently in clinical trials for autism and myotonic dystrophy, as a promising therapeutic strategy for ALS. With this aim we have evaluated the efficacy of Tideglusib in different experimental ALS models both in vitro and in vivo. Moreover, we observed that GSK-3β activity is increased in lymphoblasts from sporadic ALS patients, with a simultaneous increase in TDP-43 phosphorylation and cytosolic TDP-43 accumulation. Treatment with Tideglusib decreased not only phospho-TDP-43 levels but also recovered its nuclear localization in ALS lymphoblasts and in a human TDP-43 neuroblastoma model. Additionally, we found that chronic oral treatment with Tideglusib is able to reduce the increased TDP-43 phosphorylation in the spinal cord of Prp-hTDP-43A315T mouse model. Therefore, we consider Tideglusib as a promising drug candidate for ALS, being proposed to start a clinical trial phase II by the end of the year., This research was funded by Madrid Community (B2017/BMD3813 ELA-Madrid), ISCiii (CIBERNED CB18/05/00040 and CB06/05/0089) and AEI (grant RTI2018-096100-B-I00 to Á.M.-R., PID2019-105600RB-I00 to A.M. and RTI2018-0988885-B-I00 to E.d.L.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Improved controlled release and brain penetration of the small molecule S14 using PLGA nanoparticles

  • Nozal, Vanesa
  • Rojas-Prats, Elisa
  • Maestro, Inés
  • Gil, Carmen
  • Pérez, Daniel I.
  • Martínez Gil, Ana
14 p.-8 fig.-4 tab., Phosphodiesterase 7 (PDE7) is an enzyme responsible for the degradation of cyclic adenosine monophosphate (cAMP), an important cellular messenger. PDE7’s role in neurotransmission, expression profile in the brain and the druggability of other phosphodiesterases have motivated the search for potent inhibitors to treat neurodegenerative and inflammatory diseases. Different heterocyclic compounds have been described over the years; among them, phenyl-2-thioxo-(1H)-quinazolin-4-one, called S14, has shown very promising results in different in vitro and in vivo studies. Recently, polymeric nanoparticles have been used as new formulations to target specific organs and produce controlled release of certain drugs. In this work, we describe poly(lactic-co-glycolic acid) (PLGA)-based polymeric nanoparticles loaded with S14. Their preparation, optimization, characterization and in vivo drug release profile are here presented as an effort to improve pharmacokinetic properties of this interesting PDE7 inhibitor., This research was supported by MINECO (grant RTC-2015-3439-1 and PID2019-105600RB-I00), ISCiii CIBERNED (CB18/05/00040), MECD (FPU14-00204 to E.R.-P. and FPU16-04466 to V.N.) and H2020-MSCA-ITN-2017 (grant no. 765912 to I.M.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Editorial: Tau Protein: Mechanisms From Health to Degeneration

  • Lastres-Becker, Isabel
© 2021 Lastres-Becker., In this Editorial, we are going to go through the essential points of the latest news published on the topic “TAU protein: mechanisms from health to degeneration.” In recent years, it has been shown that TAU protein is involved in multiple cellular mechanisms, which alterations are associated with neurodegenerative diseases called tauopathies. TAU is a neuronal microtubule-associated protein important for axonal transport which, under pathological conditions, forms aberrant assembly into insoluble aggregates. This led to synaptic dysfunction and neural cell death in a range of neurodegenerative disorders. Within this Editorial we will discover that the works presented are focus on three essential hallmarks of TAU: (1) TAU phosphorylation; (2) TAU oligomers and (3) TAU signaling (Figure 1). Altogether, finally, in this special issue, we will uncover several TAU-based therapies for these groups of diseases., This work was supported by a Spanish Ministry of Economy and Competitiveness Grants Refs. PID2019-105600RB-I00 to IL-B; General Council for Research and Innovation of the Community of Madrid and European Structural Funds Ref. S2017/BMD-3813-ELA_Madrid to IL-B. Fundación Tatiana Pérez de Guzmán el Bueno P-043-FTPGB 2020 to IL-B. Fundela (2019/00325/001) to IL-B.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

α-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks

  • García-Yagüe, Ángel Juan
  • Lastres-Becker, Isabel
  • Stefanis, Leonidas
  • Vassilatis, Demetrios K.
  • Cuadrado, Antonio
© The Author(s) 2021., In Parkinson’s disease, the dysfunction of the dopaminergic nigrostriatal tract involves the loss of function of dopaminergic neurons of the substantia nigra pars compacta followed by death of these neurons. The functional recovery of these neurons requires a deep knowledge of the molecules that maintain the dopaminergic phenotype during adulthood and the mechanisms that subvert their activity. Previous studies have shown that transcription factor NURR1, involved in differentiation and maintenance of the dopaminergic phenotype, is downregulated by α-synuclein (α-SYN). In this study, we provide a mechanistic explanation to this finding by connecting α-SYN-induced activation of glycogen synthase kinase-3 (GSK-3) with NURR1 phosphorylation followed by proteasomal degradation. The use of sequential deletion mutants and single point mutants of NURR1 allowed the identification of a domain comprising amino acids 123-PSSPPTPSTPS-134 that is targeted by GSK-3 and leads to subsequent ubiquitination and proteasome degradation. This study provides a detailed analysis of the regulation of NURR1 stability by phosphorylation in synucleinopathies such as Parkinson’s disease., This study was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grant PID2019-110061RB-I00 for A.C and PID2019-105600RB-I00 for I.L.B.) and The Autonomous Community of Madrid (grant B2017/ BMD-3827 for A.C. and B2017/BMD-3813 for I.L.B.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

New statement about NRF2 in amyotrophic lateral sclerosis and frontotemporal dementia

  • Lastres-Becker, Isabel
  • Lago, Eva de
  • Martínez Gil, Ana
  • Fernández-Ruiz, Javier
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are related neurodegenerative disorders displaying substantial overlay, although there are substantial differences at the molecular level. Currently, there is no effective treatment for these diseases. The transcription factor NRF2 has been postulated as a promising therapeutic target as it is capable of modulating key pathogenic events affecting cellular homeostasis. However, there is little experimental evidence on the status of this pathway in both ALS and FTD. Therefore, in this work, we wanted to carry out an exhaustive analysis of this signaling pathway in both transgenic mouse models (ALS and FTD) and human samples from patients with sporadic ALS (sALS) versus controls. In samples from patients with sALS and in the transgenic model with overexpression of TDP-43A315T, we observed a significant increase in the NRF2/ARE pathway in the motor cortex and the spinal cord, indicating that NRF2 antioxidant signaling was being induced, but it was not enough to reach cellular homeostasis. On the other hand, in the transgenic FTD model with overexpression of the TDP-43WT protein in forebrain neurons, a significantly decreased expression of NQO1 in the prefrontal cortex was seen, which cannot be attributed to alterations in the NRF2 pathway. Our results show that NRF2 signature is differently affected for ALS and FTD., This work was supported by Comunidad de Madrid (grant B2017/BMD-3813), MINECO (PID2019-105600RB-I00 to A.M. and I.L-B), ISCiii CIBERNED (CB18/05/00040 to A.M. and CB06/05/0089 to J.F.-R., E.d.L., and I.L.-B.), and Fundela (2019/00325/001 to I.L.B.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Identification of a new structural family of SGK1 inhibitors as potential neuroprotective agents

  • Maestro, Inés
  • Madruga, Enrique
  • Boya, Patricia
  • Martínez Gil, Ana
12 p.-11 fig.-3 tab., SGK1 is a serine/threonine kinase involved in several neurodegenerative-related pathways such as apoptosis, neuroinflammation, ionic channel regulation, and autophagy, among others. Despite its potential role as a pharmacological target against this kind of diseases, there are no reported inhibitors able to cross the BBB so far, being a field yet to be explored. In this context, a structure-based virtual screening against this kinase was performed, pointing out the deazapurine moiety as an interesting and easy-to-derivatize scaffold. Moreover, these inhibitors are able to i) exert neuroprotection in an in vitro model of AD and ii) block mitophagy in a PRKN-independent manner, reinforcing the hypothesis of SGK1 inhibitors as neuroprotective chemical tools., This research was supported by the European Comission H2020-MSCA-ITN-2017 program (grant no. 765912, DRIVE Project), Ministerio de Ciencia e Innovación (grant PID2019-105600RB-I00), ISCiii (grant CB18/05/00040, CIBERNED) and CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGINGl+ (PTI-NEURO-AGING+), Fondos recuperación PT + Neuroaging., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Specialized proresolving mediators protect against experimental autoimmune myocarditis by modulating Ca2+ handling and NRF2 activation

  • Val-Blasco, Almudena
  • Prieto, Patricia
  • Iñigo Jaén, Rafael
  • Gil-Fernández, Marta
  • Pajares, Marta
  • Domenech, N.
  • Terrón, Verónica
  • Tamayo, María
  • Jorge, Inmaculada
  • Vázquez, Jesús
  • Bueno-Sen, A.
  • Vallejo-Cremades, Maria T.
  • Pombo-Otero, Jorge
  • Sánchez-García, Sergio
  • Ruiz-Hurtado, Gema
  • Gómez, Ana María
  • Zaragoza, Carlos
  • Crespo-Leiro, M. G.
  • López-Collazo, Eduardo
  • Cuadrado, Antonio
  • Delgado, Carmen
  • Boscá, Lisardo
  • Fernández-Velasco, María
Specialized proresolving mediators and, in particular, 5(S), (6)R, 7-trihydroxyheptanoic acid methyl ester (BML-111) emerge as new therapeutic tools to prevent cardiac dysfunction and deleterious cardiac damage associated with myocarditis progression. The cardioprotective role of BML-111 is mainly caused by the prevention of increased oxidative stress and nuclear factor erythroid-derived 2-like 2 (NRF2) down-regulation induced by myocarditis. At the molecular level, BML-111 activates NRF2 signaling, which prevents sarcoplasmic reticulum–adenosine triphosphatase 2A down-regulation and Ca2+ mishandling, and attenuates the cardiac dysfunction and tissue damage induced by myocarditis., This work was supported by the Spanish Ministry of Economy and Competitiveness and the European Regional Development Fund (SAF-2017-84777R), Instituto de Salud Carlos III (ISCIII) (PI17/01093, PI17/01344, and PI20/01482), Sociedad Española de Cardiología, Proyecto Traslacional 2019 and Asociación del Ritmo Cardiaco (SEC, España), Proyecto Asociación Insuficiencia Cardiaca (Trasplante Cardiaco) 2020, Fondo Europeo de Desarrollo Regional, Fondo Social Europeo, and CIBERCV, a network funded by ISCIII, Spanish Ministry of Science, Innovation and Universities (PGC2018-097019-B-I00), Ministerio de Economía, Industria y Competitividad/Agencia Estatal de Investigación 10.13039/501100011033 PID2020-113238RB-I00, PID2019-105600RB-I00, the Instituto de Salud Carlos III (Fondo de Investigación Sanitaria grant PRB3 [PT17/0019/0003-ISCIII-SGEFI/ERDF, ProteoRed]), and “la Caixa” Foundation (project code HR17-00247). The Centro Nacional de Investigaciones Cardiovasculares is supported by the ISCIII, the Ministerio de Ciencia, Innovación y Universidades. Dr Ruiz-Hurtado is Miguel Servet I researcher of ISCIII (CP15/00129 Carlos III Health Institute). Dr Tamayo and R.I. Jaén, and M. Gil-Fernández were or currently are PhD students funded by the Formación de Profesorado Universitario program of the Spanish Ministry of Science, Innovation and Universities (FPU17/06135; FPU16/00827, FPU1901973).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis

  • Benítez-Fernández, Rocío
  • Gil, Carmen
  • Guaza, Carmen
  • Mestre, Leyre
  • Martínez Gil, Ana
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune and degenerative disease with axonal damage and demyelination as its main features. Its dual neurological and autoimmune nature makes it a disease that is difficult to treat. Treatments that simultaneously stop the immune response while protecting and repairing the nervous system are urgent. That is of utmost importance for the primary progressive multiple sclerosis (PPMS), a rare and severe variant of MS, characterized by worsening neurological function from the onset of symptoms. In this sense, inhibitors of glycogen synthase kinase 3β (GSK3β) and phosphodiesterase 7 (PDE7) have recently shown great therapeutic potential for the treatment of demyelinating diseases. Here we investigated a dual inhibitor of these two targets, the small molecule VP3.15, in a preclinical model, which resembles primary-progressive MS (PPMS), the Theiler’s mouse encephalomyelitis virus-induced demyelinated disease (TMEV-IDD). In our study, VP3.15 ameliorates the disease course improving motor deficits of infected mice. Chronic treatment with VP3.15 also showed significant efficacy in the immunomodulation process, as well as in the proliferation and differentiation of oligodendroglial precursors, improving the preservation of myelin and axonal integrity. Therefore, our results support a treatment with the safe VP3.15 as an integrative therapeutic strategy for the treatment of PPMS., This work was supported by grants from Agencia Española de Investigación (PID2019-105600RB-I00) and Instituto de Salud Carlos III (CIBERNED, CB18/05/00040).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Multitarget hybrid fasudil derivatives as a new approach to the potential treatment of amyotrophic lateral sclerosis

  • Martín-Cámara, Olmo
  • Arribas, Marina
  • Wells, Geoffrey
  • Morales-Tenorio, Marcos
  • Martín-Requero, Ángeles
  • Porras, Gracia
  • Martínez Gil, Ana
  • Giorgi, Giorgio
  • López-Alvarado, Pilar
  • Lastres-Becker, Isabel
  • Menéndez, J. Carlos
16 p.-9 fig.-9 tab.-1 graph. abst., Hybrid compounds containing structural fragments of the Rho kinase inhibitor fasudil and the NRF2 inducers caffeic and ferulic acids were designed with the aid of docking and molecular mechanics studies. Following the synthesis of the compounds using a peptide-coupling methodology, they were characterized for their ROCK2 inhibition, radical scavenging, effects on cell viability (MTT assay), and NRF2 induction (luciferase assay). One of the compounds (1d) was selected in view of its good multitarget profile and good tolerability. It was able to induce the NRF2 signature, promoting the expression of the antioxidant response enzymes HO-1 and NQO1, via a KEAP1-dependent mechanism. Analysis of mRNA and protein levels of the NRF2 pathway showed that 1d induced the NRF2 signature in control and SOD1-ALS lymphoblasts but not in sALS, where it was already increased in the basal state. These results show the therapeutic potential of this compound, especially for ALS patients with a SOD1 mutation., This work was supported by the Comunidad de Madrid (grant B2017/BMD-3813), MINECO (grant RTI2018-097662-B-I00 to J.C.M. and PID2019-105600RB-I00 to A.M. and I.L.-B), ISCiii CIBERNED (CB18/05/00040 to A.M. and Á.M.-R. and CB06/05/0089 to I.L.-B.), and Fundela (2019/00325/001) to I.L.-B., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

TDP-43 pathology and prionic behavior in human cellular models of Alzheimer’s disease patients

  • Cuevas, Eva P.
  • Rodríguez-Fernández, Alberto
  • Palomo, Valle
  • Martínez Gil, Ana
  • Martín-Requero, Ángeles
19 p.-7 fig.-2 tab., Alzheimer’s disease (AD) is a neurodegenerative disorder for which there is currently no effective treatment. Despite advances in the molecular pathology of the characteristic histopathological markers of the disease (tau protein and β-amyloid), their translation to the clinic has not provided the expected results. Increasing evidences have demonstrated the presence of aggregates of TDP-43 (TAR DNA binding protein 43) in the postmortem brains of patients diagnosed with AD. The present research is focused on of the study of the pathological role of TDP-43 in AD. For this purpose, immortalized lymphocytes samples from patients diagnosed with different severity of sporadic AD were used and the TDP-43 pathology was analyzed against controls, looking for differences in their fragmentation, phosphorylation and cellular location using Western blot and immunocytochemical techniques. The results revealed an increase in TDP-43 fragmentation, as well as increased phosphorylation and aberrant localization of TDP-43 in the cytosolic compartment of lymphocytes of patients diagnosed with severe AD. Moreover, a fragment of approximately 25 KD was found in the extracellular medium of cells derived from severe AD individuals that seem to have prion-like characteristics. We conclude that TDP-43 plays a key role in AD pathogenesis and its cell to cell propagation., This work has been funded by AEI (grants PID2019-105600RB-I00 to AM, and grant RTI2018-096100-B-I00 to A.M-R); CM (grant B2017/BMD-3813) and ISCiii (grant CB18/05/00040, CIBERNED) and La Caixa grant LCF/BQ/PR18/11640007 to VP., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The emerging role of mixed lineage kinase 3 (MLK3) and its potential as a target for neurodegenerative diseases therapies

  • Moreno, Ricardo
  • Recio, Javier
  • Barber, Santiago
  • Gil, Carmen
  • Martínez Gil, Ana
11 p.-6 fig.-1 tab., Selective and brain-permeable protein kinase inhibitors are in preclinical development for treating neurodegenerative diseases. Among them, MLK3 inhibitors, with a potent neuroprotective biological action have emerged as valuable agents for the treatment of pathologies such as Alzheimer's, Parkinson's disease and amyotrophic lateral sclerosis. In fact, one MLK3 inhibitor, CEP-1347, reached clinical trials for Parkinson's disease. Additionally, another compound called prostetin/12k, a potent and rather selective MLK3 inhibitor has started clinical development for ALS based on its motor neuron protection in both in vitro and in vivo models. In this review, we will focus on the role of MLK3 in neuron-related cell death processes, neurodegenerative diseases, and the potential advantages of targeting this kinase through pharmacological modulation for neuroprotective treatment., This work was supporting by AEI (grant no. PID2019-105600RB-I00) and La Caixa and Luzon Foundations (grant no HR21-00931). J.R. acknowledges the “Margarita Salas” Grants of University of Alcalá, while S.D. the JAE-intro grant of CSIC (no. JAEINT_21_01622)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MBC and ECBL libraries: outstanding tools for drug discovery

  • Ginex, Tiziana
  • Madruga, Enrique
  • Martínez Gil, Ana
  • Gil, Carmen
12 p.-7 fig.-1 tab., Chemical libraries have become of utmost importance to boost drug discovery processes. It is widely accepted that the quality of a chemical library depends, among others, on its availability and chemical diversity which help in rising the chances of finding good hits. In this regard, our group has developed a source for useful chemicals named Medicinal and Biological Chemistry (MBC) library. It originates from more than 30 years of experience in drug design and discovery of our research group and has successfully provided effective hits for neurological, neurodegenerative and infectious diseases. Moreover, in the last years, the European research infrastructure for chemical biology EU-OPENSCREEN has generated the European Chemical Biology library (ECBL) to be used as a source of hits for drug discovery. Here we present and discuss the updated version of the MBC library (MBC v.2022), enriched with new scaffolds and containing more than 2,500 compounds together with ECBL that collects about 100,000 small molecules. To properly address the improved potentialities of the new version of our MBC library in drug discovery, up to 44 among physicochemical and pharmaceutical properties have been calculated and compared with those of other well-known publicly available libraries. For comparison, we have used ZINC20, DrugBank, ChEMBL library, ECBL and NuBBE along with an approved drug library. Final results allowed to confirm the competitive chemical space covered by MBC v.2022 and ECBL together with suitable drug-like properties. In all, we can affirm that these two libraries represent an interesting source of new hits for drug discovery., This research was funded by MCIN/AEI/10.13039/501100011033 (Grant No PID 2019-105600RB-I00 to AM and PID 2021-122223OB-I00 to CG) and ERDF “A way of making Europe” by the European Union, Education Spanish Ministry(Grant FPU20/03743 to EM) and the European Commission Horizon 2020 Framework Programme (Project EU-OPENSCREEN-DRIVE—GA 823893)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

TTBK1 and CK1 inhibitors restore TDP-43 pathology and avoid disease propagation in lymphoblast from Alzheimer’s disease patients

  • Martínez-González, Loreto
  • Cuevas, Eva P.
  • Tosat-Bitrian, Carlota
  • Nozal, Vanesa
  • Gil, Carmen
  • Palomo, Valle
  • Martín-Requero, Ángeles
  • Martínez Gil, Ana
12 p.-5 fig.-2 tab., Introduction: TDP-43 proteinopathy in Alzheimer’s disease (AD) patients is recently emerging as a relevant pathomolecular event that may have been overlooked. Recent results in immortalized lymphocytes from AD patients have shown not only an increase of post-translational modifications in TDP-43, such as hyperphosphorylation and fragmentation, but also its prionic behaviour and cell-to-cell disease transmission. With the main goal to advance therapeutic interventions, we present in this work different kinase inhibitors with potential to restore this pathological mechanism., Methodology: We have used immortalized lymphocytes from healthy controls and AD severe patients to evaluate the correction of TDP-43 pathology after the treatment with previously synthetized TTBK1 and CK1 inhibitors. Moreover we used the conditioned mediums of these cells to perform different disease propagation experiments., Results: TDP-43 pathology observed in lymphoblasts from severe AD patients is reduced after the treatment with TTBK1 and CK1 inhibitors (decreasing phosphorylation and increasing nuclear localisation), Furthermore, the significant increase in TDP-43 phosphorylation, cytoplasmic accumulation and aberrant F-actin protrusions (TNT-like structures) observed in control cells growing in CM from AD lymphoblasts were abolished when the CM from AD lymphoblasts treated with previously reported TTBK1 and CK1 inhibitors were used. In addition, the cytosolic transport mediated by molecular motors of the receptor cells was altered with the induced TDP-43 pathology, but it was not produced with the abovementioned pretreated CMs., Conclusion: TTBK1 and CK1 inhibitors, specially VNG1.47 and IGS2.7 compounds, restore TDP-43 pathology and avoid cell-to-cell propagation in immortalized lymphocytes from AD patients, being excellent candidates for the future therapy of this prevalent and devastating disease., This work has been partially supported by La Caixa and Luzón Foundation (grant HR21-00931), Instituto de Salud Carlos iii (grant CB18/05/00040), MCIN/AEI/10.13039/501100011033(PID2019-105600RB-I00 to AM and PID2021-128340OA-I00 to VP), MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future” (grant RYC2019-027489-I f) and Ministerio de Educación (FPU18/06310 to CT-B and FPU16/04466 to VN)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration?

  • Brackhan, Mirjam
  • Arribas-Blázquez, Marina
  • Lastres-Becker, Isabel
Although the trigger for the neurodegenerative disease process is unknown, the relevance of aging stands out as a major risk for the development of neurodegeneration. In this review, we highlighted the relationship between the different cellular mechanisms that occur as a consequence of aging and transcription factor nuclear factor erythroid-2-related factor 2 (NRF2) and the connection with the TAU protein. We focused on the relevance of NRF2 in the main processes involved in neurodegeneration and associated with aging, such as genomic instability, protein degradation systems (proteasomes/autophagy), cellular senescence, and stem cell exhaustion, as well as inflammation. We also analyzed the effect of aging on TAU protein levels and its aggregation and spread process. Finally, we investigated the interconnection between NRF2 and TAU and the relevance of alterations in the NRF2 signaling pathway in both primary and secondary tauopathies. All these points highlight NRF2 as a possible therapeutic target for tauopathies., This work was supported by Ministerio de Ciencia e Innovación, Spain (MINECO) (PID2019-105600RB-I00 to I.L.-B.), Fundación Tatiana Pérez de Guzmán el Bueno (2021/00072/001 to I.L.-B.), Biomedical Research Networking Center on Neurodegenerative Diseases ISCiii CIBERNED (CB06/05/0089 to I.L.-B.). M.B. received funding from the Instituto de Salud Carlos III (IHMC22/00032)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Transcription Factor NRF2 Has Epigenetic Regulatory Functions Modulating HDACs, DNMTs, and miRNA Biogenesis

  • Silva-Llanes, Ignacio
  • Hoon Shin, Chang
  • Jiménez-Villegas, José
  • Gorospe, Myriam
  • Lastres-Becker, Isabel
The epigenetic regulation of gene expression is a complex and tightly regulated process that defines cellular identity and is associated with health and disease processes. Oxidative stress is capable of inducing epigenetic modifications. The transcription factor NRF2 (nuclear factor erythroid-derived 2-like 2) is a master regulator of cellular homeostasis, regulating genes bearing antioxidant response elements (AREs) in their promoters. Here, we report the identification of ARE sequences in the promoter regions of genes encoding several epigenetic regulatory factors, such as histone deacetylases (HDACs), DNA methyltransferases (DNMTs), and proteins involved in microRNA biogenesis. In this research, we study this possibility by integrating bioinformatic, genetic, pharmacological, and molecular approaches. We found ARE sequences in the promoter regions of genes encoding several HDACs, DNMTs, and proteins involved in miRNA biogenesis. We confirmed that NRF2 regulates the production of these genes by studying NRF2-deficient cells and cells treated with dimethyl fumarate (DMF), an inducer of the NRF2 signaling pathway. In addition, we found that NRF2 could be involved in the target RNA-dependent microRNA degradation (TDMD) of miR-155-5p through its interaction with Nfe2l2 mRNA. Our data indicate that NRF2 has an epigenetic regulatory function, complementing its traditional function and expanding the regulatory dimensions that should be considered when developing NRF2-centered therapeutic strategies., This work was supported MINECO (SAF2016-76520-R to I.L-B., PID2019-105600RB-I00 to I.L-B) and ISCiii CIBERNED (CB06/05/0089 to I.L.-B.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Druggable cavities and allosteric modulators of the cell division cycle 7 (CDC7) kinase

  • Rojas-Prats, Elisa
  • Martínez-González, Loreto
  • Gil, Carmen
  • Ramírez, David
  • Martínez Gil, Ana
11p.-9 fig.-3 tab., Cell division cycle 7 kinase (CDC7) has been found overexpressed in many cancer cell lines being also one of the kinases involved in the nuclear protein TDP-43 phosphorylation in vivo. Thus, inhibitors of CDC7 are emerging drug candidates for the treatment of oncological and neurodegenerative unmet diseases. All the known CDC7 inhibitors are ATP-competitives, lacking of selectivity enough for success in clinical trials. As allosteric sites are less conserved among kinase proteins, discovery of allosteric modulators of CDC7 is a great challenge and opportunity in this field. Using different computational approaches, we have here identified new druggable cavities on the human CDC7 structure and subsequently selective CDC7 inhibitors with allosteric modulation mainly targeting the pockets where the interaction between this kinase and its activator DBF4 takes place., This research was supported by La Caixa and Luzón Foundation (grant no. HR21-00931 to A.M., C.G. and L.M-G.), MCIN/AEI/10.13039/501100011033 (grant no. PID2019-105600RB-I00 to A.M.), MECD (FPU14/00204 to E.R.P.), Agencia Nacional de Investigación y Desarrollo - Chile (ANID Fondecyt Regular grant no. 1220656 and ANID – MILENIO – NCN19_038 to D.R.), European Union Next Generation EU/PRTR (PTI + Neuroaging to L.M-G and A.M.) and Spanish Health Institute Carlos III (grant no. CB18/05/00040 to L.M-G, and A.M.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Casein kinase 1 inhibitor avoids TDP-43 pathology propagation in a patient-derived cellular model of amyotrophic lateral sclerosis

  • Cuevas, Eva P.
  • Martínez-González, Loreto
  • Gordillo, Clara
  • Tosat-Bitrian, Carlota
  • Pérez de la Lastra, Carmen
  • Sáenz, Amets
  • Gil, Carmen
  • Palomo, Valle
  • Martín-Requero, Ángeles
  • Martínez Gil, Ana
16 p.-10 fig.-2 tab., Amyotrophic lateral sclerosis is a fatal neurodegenerative disease without a cure to reverse its progression. Its main hallmark is the nuclear protein TDP-43, which undergoes different post-translational modifications leading to a loss of function in the nucleus and an increase in toxicity in the cytoplasm. Previous reports have indicated that pathogenic TDP-43 exhibits prion-like propagation in various contexts. With the aim of advancing therapeutics focused on preventing the propagation of TDP-43 pathology, we studied the potential role of pathogenic TDP-43 in lymphoblasts from sporadic ALS patients. We used lymphoblastoid cell lines from sporadic ALS patients as a source of pathogenic forms of TDP-43, and healthy human cells (lymphoblasts, myoblasts, neuroblastoma SH-SY5Y, or osteosarcoma U2OS) as recipient cells to investigate the seeding and spread of TDP-43 proteinopathy. Furthermore, we evaluated the potential of targeting TDP-43 phosphorylation with a CK-1 inhibitor to prevent the propagation of the pathology. The results presented herein indicate that pathogenic forms of TDP-43 are secreted into the extracellular medium of sporadic ALS lymphoblasts and could be transported by extracellular vesicles, spreading TDP-43 pathology to healthy cells. Moreover, tunneling nanotubes have also been discovered in pathological cells and may be involved in the transport of TDP-43. Interestingly, targeting TDP-43 phosphorylation with an in-house designed CK-1 inhibitor (IGS2.7) was sufficient to halt TDP-43 pathology transmission, in addition to its known effects on restoring the homeostasis of TDP-43 protein in patients-derived cells., Funding support from La Caixa and Luzón Foundation (grant no. HR21–00931), MCIN/AEI /10.13039/501100011033 (grant no. PID2019-105600RB-I00 to A.M. and E.P·C. and PID2021-128340OA-I00, CNS2022–135852 and RYC2019–027489-I to V.P.), Consejo Superior de Investigaciones Cientificas (PTI+ Neuroaging, European Union Next Generation EU/PRTR), Spanish Health Institute Carlos III (grant no. CB18/05/00040 to E.P.C, L.M-G, C. T-B., V.P., A.M.R. and A.M.) and Ministerio de Educación (grant no FPU18/06310 to C.T.B.) are acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Functional characterization of a familial ALS-associated missense TBK1 (p-Arg573Gly) mutation in patient-derived lymphoblasts

  • Porras, Gracia
  • Ruiz, Silvana
  • Maestro, Inés
  • Borrego-Hernández, Daniel
  • García-Redondo, Alberto
  • Martínez Gil, Ana
  • Martín-Requero, Ángeles
15 p.-6 fig.-1 tab., The goal of this work was to elucidate the pathogenic mechanism of an ALS-associated missense mutation, p.Arg573Gly (R573G), in the TBK1 gene. In particular, we seek to analyze the influence of this variant on the cellular levels and the function of TBK1 in immortalized cells from an ALS patient. The patient (Code# E7) belonged to a Spanish family with autosomal dominant disease manifesting in the sixth decade as either dementia or ALS. Four control individuals without signs of neurological disease were also included in this study. Our results indicate that the R375G TBK1 mutation did not affect the levels of mRNA nor the total TBK1 content; however, we observed a significant decrease in the levels of TBK1 phosphorylation, which is essential for TBK1 activity, as well as a significant reduction in the phosphorylation of p62 and RIPK1, known substrates for TBK1. Lymphoblasts from the R573G TBK1 mutation carrier patient display pathological TDP-43 homeostasis, showing elevated levels of phosphorylated TDP-43 and accumulation of the protein in the cytosolic compartment. In addition, the functional decrease in TBK1 activity observed in the E7 patient did not alter the autophagy flux, but it seems to be enough to increase ROS levels as well as the expression of pro-inflammatory cytokine IL-6., This work has been supported by grants from the ISCiii (CIBERNED, grant no. CB18/05/00040), AEI (grant no. RTI2018-096100-B-I00 and PID2019-105600RB-I00), Comunidad de Madrid (grant no. B2017/BMD-3813), and Fundación La Caixa-Fundación Luzón (grant no. HR21-00931)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Progranulin deficiency induces mitochondrial dysfunction in frontotemporal lobar degeneration with TDP-43 inclusions

  • Rodriguez-Perinan, Guiomar
  • De la Encarnación, Ana
  • Moreno, Fermín
  • López de Munain, Adolfo
  • Martínez Gil, Ana
  • Martín-Requero, Ángeles
  • Alquézar, Carolina
  • Bartolomé Robledo, Fernando
20 p.-6 fig.-1 tab., Loss-of-function (LOF) mutations in GRN gene, which encodes progranulin (PGRN), cause frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). FTLD-TDP is one of the most common forms of early onset dementia, but its pathogenesis is not fully understood. Mitochondrial dysfunction has been associated with several neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). Here, we have investigated whether mitochondrial alterations could also contribute to the pathogenesis of PGRN deficiency-associated FTLD-TDP. Our results showed that PGRN deficiency induced mitochondrial depolarization, increased ROS production and lowered ATP levels in GRN KD SH-SY5Y neuroblastoma cells. Interestingly, lymphoblasts from FTLD-TDP patients carrying a LOF mutation in the GRN gene (c.709-1G > A) also demonstrated mitochondrial depolarization and lower ATP levels. Such mitochondrial damage increased mitochondrial fission to remove dysfunctional mitochondria by mitophagy. Interestingly, PGRN-deficient cells showed elevated mitochondrial mass together with autophagy dysfunction, implying that PGRN deficiency induced the accumulation of damaged mitochondria by blocking its degradation in the lysosomes. Importantly, the treatment with two brain-penetrant CK-1δ inhibitors (IGS-2.7 and IGS-3.27), known for preventing the phosphorylation and cytosolic accumulation of TDP-43, rescued mitochondrial function in PGRN-deficient cells. Taken together, these results suggest that mitochondrial function is impaired in FTLD-TDP associated with LOF GRN mutations and that the TDP-43 pathology linked to PGRN deficiency might be a key mechanism contributing to such mitochondrial dysfunction. Furthermore, our results point to the use of drugs targeting TDP-43 pathology as a promising therapeutic strategy for restoring mitochondrial function in FTLD-TDP and other TDP-43-related diseases., This study was supported by funding from the “Instituto de Salud Carlos III” (grant numbers CP21/00049, CP20/00007, PI21/00183 and PI22/00345), Fundación Eugenio Rodriguez Pascual (FERP-2022-5) CIBERNED (grant number CB18/05/00040), “Agencia Estatal de Investigación” (grant number RTI2018-096100-B-I00 and PID2019-105600RB-I00), “Comunidad de Madrid” (grant number B2017/BMD-3813) and Fundación La Caixa-Fundación Luzón (grant HR21-00931)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation

  • Nozal, Vanesa
  • Fernández-Gómez, Paula
  • García-Rubia, Alfonso
  • Martínez-González, Loreto
  • Cuevas, Eva P.
  • Carro, Eva
  • Palomo, Valle
  • Martínez Gil, Ana
10 p.-7 fig.-4 tab., Multitarget ligands (MTLs) have emerged as an interesting alternative for addressing complex multifactorial pathologies such as neurodegenerative diseases. However, a common challenge associated with these compounds is often their high molecular weight and low solubility, which becomes a hurdle when trying to permeate over the blood-brain barrier (BBB). In this study, we have designed two new MTLs that modulate three pharmacological targets simultaneously (tau, beta-amyloid and TAR DNA-binding protein 43). To enhance their brain penetration, we have formulated organic polymeric nanoparticles using poly(lactic-co-glycolic acid). The characterization of the formulations, evaluation of their permeability through an in vitro BBB model, and assessment of their activity on disease-representative cellular models, such as Alzheimer's disease and amyotrophic lateral sclerosis, have been conducted. The results demonstrate the potential of the new MTLs and their nanoparticle encapsulation for the treatment of neurodegenerative diseases., This work was supported by AIE (grant PID2019–105600RB-I00), La Caixa and Luzón foundations (grant HR21–00937) and MCIN/AEI /10.13039/501100011033 (grant RYC2019–027489-I)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Modulation of mitochondria–endoplasmic reticulum contacts (MERCs) by small molecules as a new strategy for restoring lipid metabolism in an amyotrophic lateral sclerosis model

  • Etxebeste-Mitxeltorena, Mikel
  • Flores-Romero, Héctor
  • Ramos-Inza, Sara
  • Masiá, Esther
  • Nenchova, Maria
  • Montesinos, Jorge
  • Martínez-González, Loreto
  • Porras, Gracia
  • Orzáez, Mar
  • Vicent, María J.
  • Gil, Carmen
  • Area-Gomez, Estela
  • García-Sáez, Ana J.
  • Martínez Gil, Ana
16 p.-15 fig.-3 tab.1 graph. abst., Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease without effective treatment. The progressive motoneuron death in ALS is associated with alterations in lipid metabolism. As its regulation occurs in mitochondria-associated endoplasmic reticulum (ER) membranes (MAMs), modulation of mitochondria-ER contacts (MERCs) is emerging as a crucial factor in MAM formation and lipid metabolism control. Using the MERLIN biosensor in a high-throughput screening within the EU-OPENSCREEN ERIC, we discovered small molecules that increase MERCs in HCT116 cells, enhancing their ability to uptake cholesterol. We demonstrated that cholesterol trafficking is decreased in an ALS patient-derived cell model, and this trafficking is restored after treatment with the discovered MERC modulator 24. Electron microscopy revealed that treatment with compound 24 increases MERCs, promotes lipid droplet formation, and restores mitochondrial cristae. Overall, the brain-permeable MERC modulator, compound 24, may serve as a valuable pharmacological tool for studying MAM function and holds potential for in vivo studies in ALS and other MAM dysfunction diseases., This research was funded by European Commission Horizon 2020 Framework Programme (Project EU-OPENSCREEN-DRIVE - GA 823893), La Caixa and Luzón Foundation (grant no. HR21-00931), Luzón Foundation (UNZUE project), MCIN/AEI/10.13039/501100011033 (grant no. PID2019-105600RB-I00 to A.M., PID2019-108806RB-I00 to M.J.V., PID2020-115048RB-I00 to M.O., and PID2022-141616OA-I00 to H.F.-R.), Consejo Superior de Investigaciones Cientificas PTI+ Neuroaging (European Union Next Generation EU/PRTR), Spanish Health Institute Carlos III (grant no. CB18/05/00040 to A.M., and CB22/12/00048 to M.J.V.), and Deutsche Forschungsgemeinschaft. (grant CRC1403 to A.-J.G.-S. and CRC1218 advanced postdoctoral grant to H.F.-R.). Finally, A.-J.G.-S. thanks to the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 817758); and H.F.-R. acknowledges support by the Ikerbasque Basque Foundation for Science, COFUND, H2020-MSCA-COFUND-2020-101034228-WOLFRAM2, and by ERDF a way of making Europe (ERDF/EU)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

RIPK1 expression and inhibition in tauopathies: implications for neuroinflammation and neuroprotection

  • Silva-Llanes, Ignacio
  • Madruga, Enrique
  • Martínez Gil, Ana
  • Lastres-Becker, Isabel
11 p.-3 fig., Tauopathies are a group of neurodegenerative diseases characterized by the alteration/aggregation of TAU protein. One of the main challenges of these diseases is that they have neither biomarkers nor pharmacological targets to stop the neurodegenerative process. Apart from the neurodegenerative process, tauopathies are also characterized by a chronic low-grade neuroinflammation process, where the receptor-interacting protein kinase 1 (RIPK1) protein plays an essential role. Our research aimed to explore the role of RIPK1 in various tauopathies. We examined mouse models of frontotemporal dementia (FTD), as well as brain tissue samples from patients with progressive supranuclear palsy (PSP), a primary form of 4R tauopathy, and Alzheimer’s disease (AD), which is considered a secondary tauopathy. Our findings show elevated levels of RIPK1 mRNA levels across various forms of tauopathies, in both mouse models and human tissue samples associated with primary and secondary TAU-related disorders. Furthermore, we investigated the potential of using a RIPK1 inhibitor, known as GSK2982772, in a mouse model as a novel treatment strategy for FTD. The data showed that GSK2982772 treatment effectively reduced the reactive astrocyte response triggered by TAUP301L overexpression. However, this RIPK1 inhibitor failed to protect against the neurodegeneration caused by elevated TAUP301L levels in the hippocampal region. These results suggest that although inhibiting RIPK1 activity may help reduce TAU-related astrogliosis in the brain, the complexity of the inflammatory pathways involved could explain the absence of neuroprotective effects against TAU-induced neurodegeneration., This work was supported by MINECO (grants PID2019-105600RB-I00 to A.M. and I.L-B, and PID2022-137065OB-I00 to I.L-B), ISCiii CIBERNED (CB06/05/0089 to IL-B and CB18/05/00040 to AM and EM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia

  • Silva-Llanes, Ignacio
  • Martín-Baquero, Raquel
  • Berrojo-Armisen, Alicia
  • Rodríguez-Cueto, Carmen
  • Fernández-Ruiz, Javier
  • Lago, Eva de
  • Lastres-Becker, Isabel
Frontotemporal dementia (FTD) causes progressive neurodegeneration in the frontal and temporal lobes, leading to behavioral, cognitive, and language impairments. With no effective treatment available, exploring new therapeutic approaches is critical. Recent research highlights the transcription factor Nuclear Factor erythroid-derived 2-like 2 (NRF2) as vital in limiting neurodegeneration, with its activation shown to mitigate FTD-related processes like inflammation. Dimethyl fumarate (DMF), an NRF2 activator, has demonstrated neuroprotective effects in a TAU-dependent FTD mouse model, reducing neurodegeneration and inflammation. This suggests DMF repositioning potential for FTD treatment. Until now, no trial had been conducted to analyze the effect of DMF on TDP-43-dependent FTD. In this study, we aimed to determine the potential therapeutic efficacy of DMF in a TDP-43-related FTD mouse model that exhibits early cognitive impairment. Mice received oral DMF treatment every other day from presymptomatic to symptomatic stages. By post-natal day (PND) 60, an improvement in cognitive function is already evident, becoming even more pronounced by PND90. This cognitive enhancement correlates with the neuroprotection observed in the dentate gyrus and a reduction in astrogliosis in the stratum lacunosum-moleculare zone. At the prefrontal cortex (PFC) level, a neuroprotective effect of DMF is also observed, accompanied by a reduction in astrogliosis. Collectively, our results suggest a potential therapeutic application of DMF for patients with TDP-43-dependent FTD., This work was supported MINECO (PID2019-105600RB-I00 and PID2022-137065OB-I00 to I.L.-B. and PID2021-128906OB-I00 to E.D.L./J.F.-R.) and ISCiii CIBERNED (CB06/05/0089 to I.L.-B./E.D.L./J.F.-R.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model

  • Silva-Llanes, Ignacio
  • Rodríguez-López, S.
  • González-Naranjo, Pedro
  • Sastre, E. del
  • López, Manuela G.
  • Páez, Juan A.
  • Campillo, Nuria
  • Lastres-Becker, Isabel
Frontotemporal dementia (FTD) comprises a group of disorders characterized by a progressive decline in behavior or language linked to the degeneration of the frontal and anterior temporal lobes followed by hippocampal atrophy. There are no effective treatments for FTD and for this reason, novel pharmacological targets, such as the endocannabinoid system (ECS), are being explored. Previous results from our laboratory showed a TAU-dependent increase in CB receptor expression in hippocampal neurons of a FTD mouse model, alongside the neuroprotective impact of CB ablation. In this study, we evaluated the therapeutic potential of a new CB antagonist (PGN36) in our TAU-dependent FTD mouse model. Six-month-old mice received stereotaxic injections of an adeno-associated virus expressing human TAU protein (AAV-TAU) into the right hippocampus and were treated daily with PGN36 (5 mg/kg, i.p.) or vehicle for three weeks. By integrating behavioral tests, RNA-seq, qPCR expression analysis, and immunofluorescence in the AAV expressing TAU mouse model, we found that PGN36 treatment reverses key features of the neurodegenerative process triggered by TAU overexpression. PGN36 treatment effectively countered TAU-induced cognitive decline by reducing TAU protein expression levels and restoring markers of synaptic plasticity. Notably, we observed neuroprotection in the dentate gyrus granular layer, which we attribute to the modulation of pyroptosis. This programmed cell death pathway, is triggered by TAU overexpression. PGN36 appears to modulate the pyroptotic cascade, thereby preventing the pyroptosis-induced neuronal loss. These findings collectively underscore the neuroprotective potential of this novel CB antagonist treatment against TAU-associated FTD., This work was supported by Fundación Tatiana Pérez de Guzmán el Bueno, MINECO (grants PID2019-105600RB-I00 and PID2022- 137065OB-I00 to I.L-B and PDC2022-133809-I00 to MGL), ISCiii CIBERNED (CB06/05/0089 to I. L-B.) and Community of Madrid ref CAM-P2022/BMD-7230 to MGL. FPU18/00630 contract to ES.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis doctoral (DoctoralThesis)

Design, synthesis, and evaluation of SGK1 inhibitors as pharmacological tolls against neurodegeneration, Diseño, síntesis y evaluación de inhibidores de SGKI como herramientas farmacológicas frente a la neurodegeneración

  • Mayordomo Madruga, Enrique
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, leída el 12/09/2025, [EN] Neurodegenerative diseases encompass a group of disorders characterized by the loss of various neuronal populations. Neurodegeneration, driven by population aging, represents a global health challenge for which no effective pharmacological alternatives have been developed, compromising not only patients’ quality of life but also the sustainability of public healthcare systems. This doctoral thesis, titled "Design, synthesis, and evaluation of SGK1 inhibitors as pharmacological tools against neurodegeneration", aims to discover new SGK1 kinase inhibitors as a pharmacological strategy for various central nervous system disorders. First, SGK1 levels have been characterized in different models related to neurodegenerative diseases, as well as in patient samples from individuals with amyotrophic lateral sclerosis, Alzheimer’s disease, or Parkinson’s disease. The results suggest that conditions such as Alzheimer’s and Parkinson’s disease could serve as attractive scenarios in which SGK1 inhibition would be beneficial. Second, in the search for potent SGK1 inhibitors capable of crossing the blood brain barrier, a virtual screening of the ECBL chemical library was conducted using a strategy based on both ligand- and structure-based drug design, following the characterization of the physicochemical and pharmaceutical properties of this chemical collection. This screening led to the identification of an initial hit with notable inhibitory potency. Through various in silico techniques, the binding mode of this compound to SGK1 was elucidated. Using medicinal chemistry strategies, a collection of inhibitors was designed and synthesized based on the initial hit, ensuring both their inhibitory potency and the necessary physicochemical properties to cross the blood-brain barrier. The pharmacokinetic behavior of the most promising compounds was studied, and the inhibition of P-glycoprotein efflux transport was validated as a strategy to increase brain levels of this family of compounds. Finally, the most promising inhibitors were evaluated in various in vitro and in vivo models related to Alzheimer’s and Parkinson’s disease. These compounds were able to reduce tau phosphorylation levels and prevent the death of dopaminergic neurons in the AAV-α-SYN mouse model. In conclusion, this doctoral thesis describes the characterization of SGK1 in neurodegeneration-related models, the design and synthesis of novel SGK1 inhibitors, and their subsequent validation as pharmacological tools against neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases, [ES] Las enfermedades neurodegenerativas constituyen un conjunto de patologías caracterizadas por la pérdida de diversas poblaciones neuronales. La neurodegeneración, impulsada por el envejecimiento poblacional, supone un desafío de salud global ante el cual no se han desarrollado alternativas farmacológicas efectivas, lo que compromete no solo la calidad de vida de los pacientes, sino también la sostenibilidad de los sistemas públicos de salud. La presente tesis doctoral, titulada “Diseño, síntesis y evaluación de inhibidores de SGK1 como herramientas farmacológicas frente a la neurodegeneración”, tiene como objetivo el descubrimiento de nuevas moléculas inhibidoras de la quinasa SGK1 como estrategia farmacológica frente a diferentes patologías del sistema nervioso central. En primer lugar, se han caracterizado los niveles de transcripción SGK1 en diferentes modelos relacionados con enfermedades neurodegenerativas, así como en muestras de pacientes con esclerosis lateral amiotrófica, enfermedad de Alzheimer o enfermedad de Parkinson. Los resultados obtenidos sugieren que patologías como la enfermedad de Alzheimer o de Parkinson podrían constituir escenarios atractivos donde la inhibición de SGK1 sería beneficiosa. En segundo lugar, en la búsqueda de inhibidores de SGK1 potentes y permeables al sistema nervioso central, se ha realizado un cribado virtual de la quimioteca ECBL mediante una estrategia basada tanto en la estructura del ligando como en la estructura de la diana, previa caracterización de las propiedades fisicoquímicas y farmacéuticas de esta librería química. Este cribado dio como resultado el hallazgo de un hit inicial con una notable potencia inhibitoria. Mediante la aplicación de diferentes técnicas in silico, se ha logrado dilucidar el modo de unión de este compuesto con SGK1. Mediante el empleo de estrategias de química médica, se ha diseñado y sintetizado una colección de inhibidores congenéricos al hit inicial, garantizando tanto su potencia inhibitoria como las propiedades fisicoquímicas necesarias para poder atravesar la barrera hematoencefálica. Se ha estudiado el comportamiento farmacocinético de los compuestos más prometedores, y se ha validado la inhibición del transporte activo de la glicoproteína P como estrategia para aumentar los niveles en cerebro de esta familia de compuestos. Finalmente, los inhibidores más prometedores han sido evaluados en diferentes modelos in vitro e in vivo relacionados con la enfermedad de Alzheimer y la enfermedad de Parkinson. Estos compuestos han sido capaces de reducir los niveles de fosforilación detau, así como de impedir la muerte de las neuronas dopaminérgicas en el modelo de ratón AAV-α-SYN. En conclusión, la presente tesis doctoral describe la caracterización de SGK1 en modelos relacionados con la neurodegeneración, el diseño y la síntesis de nuevos inhibidores de SGK1 y su posterior validación como herramientas farmacológicas frente a enfermedades neurodegenerativas como la enfermedad de Alzheimer o de Parkinson., La realización de este trabajo ha sido financiado por la Agencia Española de Investigación (AEI) a través de los proyectos PID2019-105600RB-I00 y PDC2022-133774-I00. E.M.M ha sido perceptor de un contrato predocoral (FPU20/03743) del Ministerio de Ciencia, Innovación y Universidades, Peer reviewed, in vitro - Tipos celulares - líneas inmortalizadas humanas
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Brain Permeable SGK1 Inhibitors: A Promising Therapeutic Strategy for Neurodegenerative Diseases

  • Madruga, Enrique
  • Garcia-Rubia, Alfonso
  • Sanchez-Nuñez, Carlos
  • Martinez-Gonzalez, Loreto
  • Fernandez-Escamilla, Ana María
  • Lastres-Becker, Isabel
  • Gil, Carmen
  • Martinez, Ana
A major challenge in modern medicine is developing new therapies for aging-related diseases such as neurodegenerative disorders, whose prevalence increases with longer life expectancy. Although kinase inhibitors have achieved clinical success, their development for central nervous system (CNS) disorders remains limited due to the complexity of kinase networks and poor blood–brain barrier (BBB) permeability. Serum/glucocorticoid-regulated kinase 1 (SGK1) participates in multiple signaling pathways but remains an underexplored target in neurodegeneration. Following a mixed ligand- and structure-based virtual screening, we have previously identified a brain-penetrant SGK1 inhibitor. A medicinal chemistry program based on hit expansion and optimization for BBB permeability reported here has generated a new family of SGK1 inhibitors as chemical probes that enable the investigation of SGK1’s role in neurological disorders and serve as promising starting points for drug development. These findings highlight SGK1 as a potential therapeutic target for neurodegenerative diseases, such as Alzheimer’s disease, This research was funded by AEI (grant PID2019-105600RB I00 to I.L.−B. and A.M.), ISCiii CIBERNED (grant CB18/05/ 00040 to E.M., C.G., and A.M. and CB06/05/0089 to I.L.-B.), and ICAR (project SGK4END to A.M.F.-E. and A.M.). Finally, E.M. and C.S.−N. thank MCIU (grant FPU20/03743 and FPU23/01029 respectively) while A.M.F.-E. acknowledges the Teaching Staff Retraining Grant (2023), Spanish Ministry of Universities, and CIBEST/2024/114 from Generalitat Valenci ana., Peer reviewed, Modelo experimental animal, Modelo experimental alternativo-NAM, Mamíferos - Roedores, in vitro - Tipos celulares - líneas inmortalizadas humanas